Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

American Cancer Society Study Links 12% of Colorectal Cancer Deaths to Cigarettes

February 1, 2001
Publication
Article
OncologyONCOLOGY Vol 15 No 2
Volume 15
Issue 2

In the largest prospective study of cigarette smoking and colorectal cancer mortality, researchers from the American Cancer Society report finding strong evidence that cancers of the colon and rectum are, in part, smoking related.

In the largest prospective study of cigarette smokingand colorectal cancer mortality, researchers from theAmerican Cancer Society report finding strong evidence that cancers of the colonand rectum are, in part, smoking related.

An analysis of the American Cancer Society’s Cancer PreventionStudy II appeared in a recent issue of the Journal of the National CancerInstitute (92:1888-1896, 2000). It concluded that not only is long-termcigarette smoking associated with an elevated risk of dying of colorectalcancer, but that about 12% of 1997 deaths from this cancer may be attributableto cigarette smoking.

Lowest Rates Among Nonsmokers

Ann Chao, PhD, Michael J. Thun, MD, and colleagues at theAmerican Cancer Society report that colorectal death rates were highest amongcurrent smokers and lowest among those who never smoked. "Clear benefitswere also observed among those people who had quit smoking; the longer ago, thehigher the benefit," said Dr. Chao.

In the study, current male smokers had a 32% higher death ratethan nonsmokers, and current female smokers had a death rate of 41%. The higherdeath rates increased with duration of the habit and with the number ofcigarettes smoked daily.

The rates were higher for current smokers who began smokingcigarettes at younger ages, than among those who smoked longer and morecigarettes per day.

Study Data

The Cancer Prevention Study II began enrolling approximately1 million Americans in 1982. Dr. Chao and her coauthors analyzed data on312,332 men and 469,019 women, among whom 4,432 died from either colon or rectalcancer. Data from these participants were controlled for a number of potentiallyconfounding variables including alcohol use, physical activity, family historyof colorectal cancer, vitamin use, and dietary factors.

"The size of the study allowed us to examine, in detail,gradients in smoking behavior separately in former and current smokers,"said Dr. Chao. "It also permitted us to estimate the percentage ofsmoking-related colorectal cancer deaths in the general population, which wouldhave been about 12% in 1997, or more than 6,800 people for that year," shesaid.

"The smoking epidemic in women began decades later than inmen," said Michael J. Thun, MD, vice president of epidemiology andsurveillance research for the American Cancer Society. "This may explain,in part, why the trends in colorectal cancer incidence and death rates differedbetween genders during the 1950s, 1960s, and 1970s, with male rates being higherthan female rates. As the smoking rates increased for women, the colorectalrates became very similar for both genders," said Dr. Thun. 

Articles in this issue

Book Review: Comprehensive Cancer Care: Integrating Alternative, Complementary, and Conventional Therapies
Study Details Use of Amifostine in Radiation Setting
Declines in Lung Cancer Rates-California, 1988-1997
Medicare Approves PET for Additional Cancers
Study Contributes to Evolution of Sentinel Lymph Node Biopsy for Melanoma
The Breast: Comprehensive Management of Benign and Malignant Diseases, Second Edition
Topotecan Active as First-Line Combination Therapy for Advanced Non-Small-Cell Lung Cancer
Promising Results With Motexafin for Brain Metastases and Glioblastoma Multiforme
Chemoradiotherapy Followed by Docetaxel May Increase Life Expectancy in Non-Small-Cell Lung Cancer Patients
Medicare Bill Expands Cancer Screening
Researchers Able to Predict Which Breast Cancer Patients Are at Highest Risk of Bone Metastases
Letrozole Approved as First-Line Treatment for Advanced Breast Cancer in Postmenopausal Women
American Cancer Society Study Links 12% of Colorectal Cancer Deaths to Cigarettes
Painful Osteoblastic Metastases: The Role of Nuclear Medicine
Corticosteroids in Advanced Cancer
Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
Advertisement

"Our preliminary results showed that the efficacy of fruquintinib combined with capecitabine is promising with well tolerance as maintenance therapy in RAS/BRAF wild-type mCRC,” according to lead study author, Kai Ou.

Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

Courtney Flaherty
May 9th 2025
Article

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Roman Fabbricatore
May 8th 2025
Article

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.

Atezolizumab/Trastuzumab Plus Chemotherapy Shows Efficacy in Gastric Cancer

Roman Fabbricatore
May 7th 2025
Article

Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.


Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.

JNJ-1900 Demonstrates Safety, Feasibility in Advanced Pancreatic Cancer

Roman Fabbricatore
May 5th 2025
Article

Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.

Related Content
Advertisement

"Our preliminary results showed that the efficacy of fruquintinib combined with capecitabine is promising with well tolerance as maintenance therapy in RAS/BRAF wild-type mCRC,” according to lead study author, Kai Ou.

Fruquintinib Combo Shows Early Activity in RAS/BRAF+ Metastatic CRC

Courtney Flaherty
May 9th 2025
Article

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Roman Fabbricatore
May 8th 2025
Article

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.

Atezolizumab/Trastuzumab Plus Chemotherapy Shows Efficacy in Gastric Cancer

Roman Fabbricatore
May 7th 2025
Article

Pathological complete response was higher among patients with ERBB2–positive gastric cancer or GEJ adenocarcinoma treated with atezolizumab vs without.


Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.

JNJ-1900 Demonstrates Safety, Feasibility in Advanced Pancreatic Cancer

Roman Fabbricatore
May 5th 2025
Article

Among 20 patients with advanced pancreatic cancer and available circulating tumor mutational burden data, 40% exhibited increased tumor mutational burden.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.